Navigation Links
Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
Date:3/26/2009

- First product approval from Sagent and Strides Arcolab Joint Venture -

SCHAUMBURG, Ill., March 26 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced U.S. Food and Drug Administration (FDA) approval of azithromycin for injection, a semi-synthetic, macrolide antibiotic that is used to treat a wide variety of bacterial infections. Sagent will offer azithromycin in a 500 mg vial for intravenous use. The Company anticipates the launch of azithromycin in April 2009. According to IMS, 2008 sales of azithromycin in the United States approximated $42 million.

"This approval marks an important milestone for Sagent, as azithromycin is the first product from our joint venture - established in 2007 - with Strides Arcolab," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "Strides' manufacturing and development expertise will be invaluable as we move forward with not only azithromycin, one of the world's most widely used antibiotics, but also with the more than 25 products under development by the joint venture."

Under the joint venture agreement, Sagent and Strides Arcolab are developing, supplying and marketing more than 25 injectable products for the U.S. market. Strides is responsible for developing and supplying injectable products that Sagent will market in the United States.

Since late 2007, Sagent launched eight products and currently has more than 70 Abbreviated New Drug Applications (ANDA) submissions on file with the U.S. FDA.

About Azithromycin

Azithromycin for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila'/>"/>

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
2. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
3. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
4. Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Krause, an aerospace engineer,for NASA, was giving the ... he,was confident that technology and science could solve ... one thing that science couldn,t solve.,His wife Susan ... machines,would keep her alive for awhile, she would ... 69 and is starting dialysis next month. She ...
(Date:12/14/2009)... could be linked to scans performed in 2007 , , ... are exposing patients to far more radiation than previously thought ... cancers a year, two new studies claim. , Based on ... Archives of Internal Medicine , the study authors, joined ... calling on clinicians to limit radiation exposure to patients. , ...
(Date:12/14/2009)... , , MONDAY, Dec. 14 (HealthDay News) -- Here,s good ... a cup or two of java: Coffee and tea ... diabetes. , That,s the conclusion of an Australian ... the lower your risk of diabetes. Every cup of ... the risk of diabetes, the researchers said. , ...
(Date:12/14/2009)... are linked to an increased risk of certain cancers. ... synthetic insulin preparation marketed under the trade name Lantus), ... cancers than other insulins or oral glucose lowering medications. ... important factors such as obesity that may have driven ... large randomized trial designed to examine another aspect of ...
(Date:12/14/2009)... COPD, researchers say , , MONDAY, Dec. 14 (HealthDay News) ... lung function, a finding that may help lead to ... of researchers compared lung function with genetic variants at ... genome in more than 20,000 people of European ancestry. ... variants associated with alterations in lung function. , The ...
Breaking Medicine News(10 mins):Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2
... Medicine Cabinet Day Set For Saturday October 13,Proper ... OTC Drug Abuse, CHICAGO, Oct. 8 ... treatment to adolescents, adults and their,families, said today ... an area wide "Clean Out Your Medicine Cabinet" ...
... men who have surgery for prostate cancer appear less likely ... who choose other treatment options, especially if they are younger ... a report in the Oct. 8 issue of Archives of ... treatments are still being debated because they have not yet ...
... Center researcher has been awarded a National Institutes of ... factors, in addition to traditional predictors, can be useful ... disease. , Kevin A. Fiscella, M.D., M.P.H., associate professor ... by the National Heart, Lung and Blood Institute, part ...
... Study finds it outperforming other forms of treatment , ... the best chance of long-term survival for prostate cancer ... University found that prostate cancer patients who had surgery ... 10 years than men who had other types of ...
... of Parkinson,s patients more likely to develop dementia, study ... Relatives of people with Parkinson,s disease face up to ... suggests a new study that says genetics could be ... of the central nervous system, such as impaired motor ...
... WASHINGTON, Oct. 8 Crowell & Moring LLP ... Rhoad to the firm,s,Health Care and False Claims ... represents both health care and government contract clients,in ... Claims Act,(FCA), antitrust claims, and criminal and civil ...
Other Medicine News:Health News:Rosecrance and Chicago's Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs 2Health News:Rosecrance and Chicago's Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs 3Health News:Swiss study suggests surgery may offer best chance of long-term prostate cancer survival 2Health News:Study to consider social risk in guiding prevention of heart disease 2Health News:Surgery Best Bet for Prostate Cancer Survival 2Health News:Parkinson's Linked to Risk of Alzheimer's 2Health News:Crowell & Moring's Expanding Health Care Litigation Practice Gains Experienced Litigator 2Health News:Crowell & Moring's Expanding Health Care Litigation Practice Gains Experienced Litigator 3
(Date:12/14/2009)... HEIGHTS, N.J., Dec. 14 Authentidate ... worldwide provider of secure Health Information Exchange ... Home Care of the Carolinas ("HCC"), a ... ("AMI"), a durable medical equipment supplier, have ... streamline and standardize processes for the completion ...
(Date:12/14/2009)... HOPKINTON, Mass., Dec. 14 ... CALP ), a leading provider of tools and ... today announced that it has completed the sale ... provides in-vivo pre-clinical CRO services, to Taconic Farms, ... acquired by Caliper as part of Caliper,s acquisition ...
(Date:12/14/2009)... SAN DIEGO, Dec. 14 ... Merck & Co., Inc., through an affiliate, an exclusive ... Pseudomonas -based recombinant protein expression technology for the production ... the development of an undisclosed vaccine candidate. ,, ... is eligible to receive approximately $52 million in upfront ...
Breaking Medicine Technology:Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 2Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 3Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 4Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 2Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 3Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 4IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests 55679 1IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests 55679 2BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 1BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 2BloodStor 28TM 29 Stem Cell Biopreservation Media Platform Launched by BioLife Solutions 13734 3Former Veterans Affairs Secretary Joins Integrated Medical Systems Advisory Board 55676 1Former Veterans Affairs Secretary Joins Integrated Medical Systems Advisory Board 55676 2Former Veterans Affairs Secretary Joins Integrated Medical Systems Advisory Board 55676 3
... Development Program in Multiple Myeloma, SOUTH ... Inc.,today announced that patient dosing has commenced ... the safety and efficacy of Proteolix,s lead ... and,dexamethasone in patients with relapsed multiple myeloma. ...
... COPENHAGEN, Denmark, July 9 Summary: Genmab,has completed ... of ofatumumab,in combination with fludarabine and cyclophosphamide to ... announced today it has completed recruitment of,56 patients ... (R)) in,combination with fludarabine and cyclophosphamide (FC) to ...
Other Medicine Technology:Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma 2Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma 3Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study 2Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: